Showing 4051-4060 of 4164 results for "".
- Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-in-the-phase-2-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2477037/Aerie Pharmaceuticals announced that patient enrollment in its phase 2 clinical trial of AR-1105 in patients with macular edema due to retinal vein occlusion (RVO) is complete several weeks ahead of schedule. AR-1105 is an investigational sustained-release, bioerodible intravitreal implant contai
- Sight Sciences: International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI Surgical System Predicate Device (VISCO360)https://modernod.com/news/sight-sciences-international-migs-study-confirms-long-term-safety-and-efficacy-of-the-omni-surgical-system-predicate-device-visco360/2477032/Sight Sciences announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm’s Canal using one of the OMNI
- Aerpio Pharmaceuticals Announces Review of Strategic Alternativeshttps://modernod.com/news/aerpio-pharmaceuticals-announces-review-of-strategic-alternatives/2477023/Aerpio Pharmaceuticals announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the company’s clinical assets and cash resources, which amounted to $48.2 million as of June 30, 2019. The Boar
- Alcon Announces Findings from IRIS Registry Analyses on Real-World Cataract Patients at AAOhttps://modernod.com/news/alcon-announces-findings-from-iris-registry-analyses-on-real-world-cataract-patients-at-aao/2477012/Alcon announced findings from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) that support the clinical value of the AcrySof platform. The IRIS Registry was used to assess characteristics and complications of IOL implantation after cataract surgery, according t
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c
- PanOptica: Anti-VEGF Eye Drop Shows Promise in Treatment of Wet AMDhttps://modernod.com/news/panoptica-anti-vegf-eye-drop-shows-promise-in-treatment-of-wet-amd/2476992/PanOptica reported positive clinical data for PAN-90806, a once-daily topical formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases, according to a company news release. At the Ophthalmology Innovation Summit at
- Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Diseasehttps://modernod.com/news/harbour-biomed-announces-completion-of-phase-2-study-in-china-of-hbm9036-in-patients-with-moderate-to-severe-dry-eye-disease/2476993/Harbour BioMed (HBM) announced completion of a phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe dry eye disease (DED). The study results, combined with previous results from HBM’s partner HanAll’s clinical
- Topline Results From Phase 2 Trial Show Nicox’s Glaucoma Drug Candidate NCX 470 Meets Primary Endpointhttps://modernod.com/news/topline-results-from-phase-2-trial-show-nicoxs-glaucoma-drug-candidate-ncx-470-meets-primary-endpoint/2476931/Nicox SA announced positive topline results from its US multicenter, Dolomites dose-response phase 2 clinical trial evaluating investigational NCX 470, a novel second-generation nitric oxide (NO)-donating bimatoprost analog, compared to latanoprost ophthalmic solution 0.005% in 433 patients with
- GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase 3 Trial of GS010 for the Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-3-trial-of-gs010-for-the-treatment-of-lhon/2476910/GenSight Biologics reported the first set of results from week 96 of the RESCUE phase 3 clinical trial, which evaluated the efficacy and safety of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditary Optic Neuropat
- American Academy of Optometry Foundation Announces the 2019 Beta Sigma Kappa (BSK) Research Fellowship Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2019-beta-sigma-kappa-bsk-research-fellowship-recipient/2476908/The American Academy of Optometry Foundation (AAOF) in collaboration with the Beta Sigma Kappa International Optometric Honor Society, has announced Sima T. Mozdbar, OD, as the 2019 recipient of the Beta Sigma Kappa (BSK) Research Fellowship. Dr. Mozdbar is an Adjunct Clinical Professor at the Un